<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126473</url>
  </required_header>
  <id_info>
    <org_study_id>EL-004</org_study_id>
    <nct_id>NCT04126473</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele</brief_title>
  <official_title>A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients With Cystic Fibrosis With at Least One G542X Allele</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eloxx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eloxx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of
      multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X
      allele.

      Up to 16 patients will be enrolled in the trial; a minimum of 4 patients will be homozygotes
      to G542X, and the remaining patients will be compound heterozygotes with G542X and with one
      of the other allowed mutations.

      Each patient will receive 4 escalating doses as follows:

        -  0.3 mg/kg per day SC

        -  0.75 mg/kg per day SC

        -  1.5 mg/kg per day SC

        -  An individualized dose, as high as 3.0 mg/kg per day SC, based upon the patients
           observed safety and tolerability, PK at previous doses and the results of laboratory
           tests
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs associated with different dose levels of ELX-02</measure>
    <time_frame>From the time of first dosing through the follow-up visit, an average of approximately 9 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration curve from time zero to 24 hours (AUC0-24)</measure>
    <time_frame>Day 1 of treatment periods 1, 2, 3, and 4</time_frame>
    <description>Full PK profile 12 blood samples over 24 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Day 1 of treatment periods 1, 2, 3, and 4</time_frame>
    <description>Full PK profile 12 plasma samples over 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 1 hour post dose (C1h)</measure>
    <time_frame>Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7, and 14 of treatment period 4</time_frame>
    <description>Sparse sampling, blood sampling only, pre-dose and 1 hour post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in forced expiratory volume (FEV1)</measure>
    <time_frame>Screening, Days 1 &amp; 7 of treatment periods 1-3, and Days 1, 7, and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in forced vital capacity (FVC)</measure>
    <time_frame>Screening, Days 1 &amp; 7 of treatment periods 1-3, and Days 1, 7, and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in forced expiratory flow at 25-75% (FEF25-75)</measure>
    <time_frame>Screening, Days 1 &amp; 7 of treatment periods 1-3, and Days 1, 7, and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in baseline sweat chloride concentration</measure>
    <time_frame>Screening, Days 1 &amp; 7 of treatment periods 1-3, and Days 1, 7, and 14 of treatment period 4, and 4 weeks following last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Genetic Disease</condition>
  <condition>Nonsense Mutation</condition>
  <condition>Cystic Fibrosis With Meconium Ileus</condition>
  <arm_group>
    <arm_group_label>ELX-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eukaryotic ribosomal selective glycoside (ERSG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELX-02</intervention_name>
    <description>ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).</description>
    <arm_group_label>ELX-02</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients must meet the following criteria to participate in this study:

          1. Males and females age 18 years and above; in countries where permitted, males and
             females age 16 years and above

          2. A confirmed diagnosis of nmCF with a documented G542X mutation, homozygote, or
             compound heterozygote with one of the specified mutations. For heterozygotes, one
             mutation has to be G542X, and the second mutation has to be one of the following Class
             1 mutations: R1162X, W1282X, or R553X. Patients with one G542X allele and a second
             allele that is not in the above list may be potentially allowed but only after
             discussion on a case by case basis with and written approval from the Sponsor.

          3. Documented SCC ≥ 60 mEq

          4. FEV1 ≥ 40% predicted normal for age, gender and height at Screening (Knudson Equation)

          5. Body Mass Index (BMI) of 19.0 to 30.0 kg/m2 (inclusive).

        Patients with any of the following characteristics/conditions will not be included in the
        study:

          1. Participation in clinical study including administration of any investigational drug
             or device in the last 30 days or 5 half-lives (whichever is longer) prior to
             investigational product dosing in the current study

          2. History of any organ transplantation

          3. Major surgery within 180 days (6 months) of Screening

          4. Patients without documented prior aminoglycoside exposure who have a mitochondrial
             mutation that has been shown to increase sensitivity to aminoglycosides

          5. Known allergy to any aminoglycoside

          6. Patients with any abnormality at ENT screening, that indicates the presence of a
             vestibular toxicity associated with prior exposure to aminoglycosides.

          7. Dizziness Handicap Inventory (DHI)-H score at screening must be &gt;16

          8. Patients receiving CFTR modulators within 2 months of study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eloxx Pharmaceuticals</last_name>
    <phone>1-781-577-5300</phone>
    <email>CTI@eloxxpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Gleiber, MD</last_name>
      <phone>0049 69 6301 6336</phone>
      <email>wolfgang.gleiber@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Metskhovrishvili</last_name>
      <phone>0049 69 6301 84301</phone>
      <email>tamara.metskhovrishvili@kgu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Wolfgang Gleiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Shteinberg, MD</last_name>
      <phone>+972-4-8250419</phone>
      <email>MichalSh4@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Einat Ben Shoshan</last_name>
      <phone>+972-4-8250419</phone>
      <email>EinatBe2@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Michal Shteinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eitan Kerem, MD</last_name>
      <phone>+972-2-5844702</phone>
      <email>EitanK@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Thea Pugatsch, MD</last_name>
      <phone>+972-2-5844702</phone>
      <email>Pthea@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Eitan Kerem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center</name>
      <address>
        <city>Petach Tikvah</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meir Mei-Zahav</last_name>
      <email>meir_zahav@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Zvia Dekel</last_name>
      <phone>+972-03-925-3934</phone>
      <email>Zviade@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.eloxxpharma.com</url>
    <description>Eloxx Pharmaceuticals Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aminoglycoside</keyword>
  <keyword>Nonsense Mutation</keyword>
  <keyword>Translational read through</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Meconium Ileus</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

